Cell-to-cell heterogeneity in gene expression is a widespread phenomenon, and may play important roles in cellular differentiation, function and disease development. Human Cell Atlas aims to profile gene expression in every single human cells. Recent studies have implicated a potential role of chromatin in the heterogeneity in gene expression. Understanding the mechanisms of cellular heterogeneity requires simultaneous measurement of RNA and occupancy of histone modifications and transcription factors on chromatin due to their critical roles in transcriptional regulation.

This technology includes Spodoptera frugiperda (Sf9) cells which were developed to produce recombinant adeno-associated virus. The cells maintain a copy of the vector genome and for production, require infection with a single baculovirus that expresses either structural and nonstructural proteins to produce rAAV, or the non-structural (Rep) proteins to produce ceDNA.

This technology includes design enhancements to transcatheter mitral cerclage annuloplasty. They include a device to convert from crossing guidewire to tension element, refinements to the tension element which incorporates a coronary artery protection device, a target/capture/snare device, a wishbone locking device, and a cutting device.

This technology includes a family of transcatheter endovenous intramyocardial tether (MIRTH) procedures to impose myocardial constraint on the LV (MIRTH), LV and RV (SCIMITAR), and cardiac resynchronization procedures. Included is a set of advanced cardiac treatment technologies that focus on minimally invasive procedures for heart patients. The main technology is the transcatheter endovenous intramyocardial tether (MIRTH) procedure, which is designed to apply physical constraint to the left ventricle (LV) of the heart.

The technology described involves the use of a compound called prazole as an anti-viral agent specifically targeting HIV-1. It was found that prazole binds to a protein called Tsg101, which is crucial for the virus's life cycle. This binding disrupts the normal interaction of Tsg101 with another protein, ubiquitin, thereby inhibiting the release of HIV-1 particles from infected cells. Additionally, the interference caused by prazole leads to the degradation of the viral protein Gag within host cells.

This technology includes the combination of a kinase inhibitor (specifically ibrutinib) with a bispecific antibody (specifically a CD19/CD3 bispecific antibody) to be used to treat cancer. CD19/CD3 bispecific antibodies (bsAbs) can be used to recruit endogenous T cells against CD19+ tumor cells via the formation of cytolytic synapses. lbrutinib, a BTK inhibitor, has been shown to normalize T cell dysfunction characteristic of CLL.

This technology includes an electronic method for fringe scanning in grating-based phase-contrast imaging, which enhances x-ray phase-contrast imaging. Traditional methods use high-density gratings and require fine grating fringes, finer than the detector's resolution, necessitating fringe scanning to obtain phase-contrast information. This process typically involves complex and precise movements of a grating for each image, challenging in applications like medical computed tomography that demand rapid gantry rotation and acquisition of numerous projection images in less than a second.

This technology includes a novel vaccine for forming autoantibodies against apoC-III, a plasma enzyme that inhibits lipolysis. The vaccine can possibly be used to treat patients with high triglycerides and are at risk for pancreatitis and cardiovascular disease. This disclosure describes an ApoC3 immunogen that includes an antigenicApoC3 peptide linked to a bacteriophage virus-like-particle (VLP) immunogenic carrier.

This technology includes a fully automated computer aided diagnosis system to quantify myocardial blood flow (MBF) and myocardial perfusion reserve (MPR) pixel maps from the first-pass contrast-enhanced cardiac magnetic resonance (CMR) perfusion images. This system performs automated image registration, motion compensation, segmentation, and modeling to extract quantitative features from different myocardial regions of interest.

This technology includes a procedure for novel virus identification in a variety of human specimens by solexa high-throughput sequencing, which allows for the screening a large number of clinical specimens for novel virus discovery in a highly efficient and relatively economical method. By using this technique, we have successfully identified a novel parvovirus from samples of seronegative hepatitis patients.